Attys Get $4.5M Of $22M Aegerion Drug Marketing Settlement

Law360, New York (December 7, 2017, 1:25 PM EST) -- A Massachusetts federal judge on Wednesday awarded $4.45 million in fees to attorneys who secured a $22.25 million settlement to end an investor class action accusing Aegerion Pharmaceuticals Inc. of hiding from shareholders the off-label marketing of the cholesterol drug Juxtapid.

U.S. District Judge Mark L. Wolf awarded the attorneys’ fees, worth 20 percent of the settlement fund, as well as litigation expenses worth $184,526, saying the amounts are “fair and reasonable.”

“Judge Wolf, as always, gave the matter serious, in-depth attention and rendered an appropriate decision,”...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

KBC Asset Management NV et al v. Aegerion Pharmaceuticals, Inc. et al


Case Number

1:14-cv-10105

Court

Massachusetts

Nature of Suit

Securities/Commodities

Judge

Mark L. Wolf

Date Filed

January 15, 2014

Law Firms

Companies

Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.